Clinical Trials Directory

Trials / Completed

CompletedNCT02055274

Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease

A Randomized, Double-blinded, Multiple Ascending Dose Study in Patients With Early-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
39 (actual)
Sponsor
Luye Pharma Group Ltd. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to characterize the pharmacokinetics (PK) of LY03003 following multiple escalating intramuscular injections, as compared to Neupro patch and to evaluate the safety and tolerability and preliminary efficacy of multiple ascending dose (MAD) of LY03003 following intramuscular injections.

Conditions

Interventions

TypeNameDescription
DRUGLY03003
DRUGNeupro

Timeline

Start date
2013-10-01
Primary completion
2015-08-01
Completion
2015-08-01
First posted
2014-02-05
Last updated
2015-10-21

Locations

5 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02055274. Inclusion in this directory is not an endorsement.

Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease (NCT02055274) · Clinical Trials Directory